Literature DB >> 27182492

The Correlation of Skeletal and Cardiac Muscle Dysfunction in Duchenne Muscular Dystrophy.

Andrew D Posner1, Jonathan H Soslow2, W Bryan Burnette3, Aihua Bian4, Ayumi Shintani4, Douglas B Sawyer5, Larry W Markham2.   

Abstract

BACKGROUND: Duchenne muscular dystrophy (DMD) is characterized by progressive skeletal muscle and cardiac dysfunction. While skeletal muscle dysfunction precedes cardiomyopathy, the relationship between the progressive decline in skeletal and cardiac muscle function is unclear. This relationship is especially important given that the myocardial effects of many developing DMD therapies are largely unknown.
OBJECTIVE: Our objective was to assess the relationship between progression of skeletal muscle weakness and onset of cardiac dysfunction in DMD.
METHODS: A total of 77 DMD subjects treated at a single referral center were included. Demographic information, quantitative muscle testing (QMT), subjective muscle strength, cardiac function, and current and retrospective medications were collected. A Spearman rank correlation was used to evaluate for an association between subjective strength and fractional shortening. The effects of total QMT and arm QMT on fractional shortening were examined in generalized least square with and without adjustments for age, ambulatory status, and duration of corticosteroids and cardiac specific medications.
RESULTS: We found a significant correlation between maintained subjective skeletal muscle arm and leg strength and maintained cardiac function as defined by fractional shortening (rho=0.47, p=0.004 and rho=0.48, p=0.003, respectively). We also found a significant association between QMT and fractional shortening among non-ambulatory DMD subjects (p=0.03), while this association was not significant in ambulatory subjects.
CONCLUSIONS: Our findings allow us to conclude that in this population, there exists a significant relationship between skeletal muscle and cardiac function in non-ambulatory DMD patients. While this does not imply a causal relationship, a possible association between skeletal and cardiac muscle function suggests that researchers should carefully monitor cardiac function, even when the primary outcome measures are not cardiac in nature.

Entities:  

Keywords:  Ambulation; Cardiac dysfunction; Cardiomyopathy; Duchenne muscular dystrophy; Skeletal muscle dysfunction

Mesh:

Year:  2016        PMID: 27182492      PMCID: PMC4864001          DOI: 10.3233/JND-150132

Source DB:  PubMed          Journal:  J Neuromuscul Dis


  24 in total

Review 1.  Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex.

Authors:  Basil J Petrof
Journal:  Am J Phys Med Rehabil       Date:  2002-11       Impact factor: 2.159

2.  Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy.

Authors:  B J Boland; P L Silbert; R V Groover; P C Wollan; M D Silverstein
Journal:  Pediatr Neurol       Date:  1996-01       Impact factor: 3.372

3.  Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support.

Authors:  Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde
Journal:  J Biomed Inform       Date:  2008-09-30       Impact factor: 6.317

Review 4.  Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions.

Authors:  Christopher F Spurney
Journal:  Muscle Nerve       Date:  2011-07       Impact factor: 3.217

5.  Cardiac dysfunction with Becker muscular dystrophy.

Authors:  M Saito; H Kawai; M Akaike; K Adachi; Y Nishida; S Saito
Journal:  Am Heart J       Date:  1996-09       Impact factor: 4.749

6.  Exclusive skeletal muscle correction does not modulate dystrophic heart disease in the aged mdx model of Duchenne cardiomyopathy.

Authors:  Nalinda B Wasala; Brian Bostick; Yongping Yue; Dongsheng Duan
Journal:  Hum Mol Genet       Date:  2013-03-03       Impact factor: 6.150

Review 7.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

Review 8.  Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care.

Authors:  Katharine Bushby; Richard Finkel; David J Birnkrant; Laura E Case; Paula R Clemens; Linda Cripe; Ajay Kaul; Kathi Kinnett; Craig McDonald; Shree Pandya; James Poysky; Frederic Shapiro; Jean Tomezsko; Carolyn Constantin
Journal:  Lancet Neurol       Date:  2009-11-27       Impact factor: 44.182

9.  All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy.

Authors:  Gernot Schram; Anne Fournier; Hugues Leduc; Nagib Dahdah; Johanne Therien; Michel Vanasse; Paul Khairy
Journal:  J Am Coll Cardiol       Date:  2013-01-23       Impact factor: 24.094

10.  Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Larry W Markham; Kathi Kinnett; Brenda L Wong; D Woodrow Benson; Linda H Cripe
Journal:  Neuromuscul Disord       Date:  2008-04-23       Impact factor: 4.296

View more
  12 in total

1.  The Role of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Duchenne Muscular Dystrophy Cardiomyopathy.

Authors:  Jonathan H Soslow; Meng Xu; James C Slaughter; Kimberly Crum; Joshua D Chew; W Bryan Burnette; Yan Ru Su; Kelsey Tomasek; David A Parra; Larry W Markham
Journal:  J Card Fail       Date:  2019-02-11       Impact factor: 5.712

2.  miR-208b modulating skeletal muscle development and energy homoeostasis through targeting distinct targets.

Authors:  Liangliang Fu; Heng Wang; Yinlong Liao; Peng Zhou; Yueyuan Xu; Yunxia Zhao; Shengsong Xie; Shuhong Zhao; Xinyun Li
Journal:  RNA Biol       Date:  2020-02-24       Impact factor: 4.652

3.  Leveraging cardiac magnetic resonance imaging to assess skeletal muscle progression in Duchenne muscular dystrophy.

Authors:  Jacob A Kaslow; Andrew G Sokolow; Thomas Donnelly; Maciej S Buchowski; Bruce M Damon; Larry W Markham; W Bryan Burnette; Jonathan H Soslow
Journal:  Neuromuscul Disord       Date:  2022-02-04       Impact factor: 3.538

4.  Beyond ambulation: Measuring physical activity in youth with Duchenne muscular dystrophy.

Authors:  Mary Killian; Maciej S Buchowski; Thomas Donnelly; W Bryan Burnette; Larry W Markham; James C Slaughter; Meng Xu; Kimberly Crum; Bruce M Damon; Jonathan H Soslow
Journal:  Neuromuscul Disord       Date:  2020-02-20       Impact factor: 4.296

Review 5.  Heart Rate Variability and Cardiopulmonary Dysfunction in Patients with Duchenne Muscular Dystrophy: A Systematic Review.

Authors:  Talita Dias da Silva; Thais Massetti; Tânia Brusque Crocetta; Carlos Bandeira de Mello Monteiro; Alex Carll; Luiz Carlos Marques Vanderlei; Carlie Arbaugh; Fernando Rocha Oliveira; Luiz Carlos de Abreu; Celso Ferreira Filho; John Godleski; Celso Ferreira
Journal:  Pediatr Cardiol       Date:  2018-04-25       Impact factor: 1.655

6.  Increased Number of Circulating CD8/CD26 T Cells in the Blood of Duchenne Muscular Dystrophy Patients Is Associated with Augmented Binding of Adenosine Deaminase and Higher Muscular Strength Scores.

Authors:  Jonathan H Soslow; Larry W Markham; W Bryan Burnette; Cristi L Galindo; Igor Feoktistov; Frank J Raucci; Bruce M Damon; Douglas B Sawyer; Sergey Ryzhov
Journal:  Front Pharmacol       Date:  2017-12-18       Impact factor: 5.810

7.  Natural History of Cardiomyopathy in Adult Dogs With Golden Retriever Muscular Dystrophy.

Authors:  Lee-Jae Guo; Jonathan H Soslow; Amanda K Bettis; Peter P Nghiem; Kevin J Cummings; Mark W Lenox; Matthew W Miller; Joe N Kornegay; Christopher F Spurney
Journal:  J Am Heart Assoc       Date:  2019-08-14       Impact factor: 5.501

Review 8.  The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review.

Authors:  Shelagh M Szabo; Renna M Salhany; Alison Deighton; Meagan Harwood; Jean Mah; Katherine L Gooch
Journal:  Orphanet J Rare Dis       Date:  2021-05-22       Impact factor: 4.123

9.  Natural History of Histopathologic Changes in Cardiomyopathy of Golden Retriever Muscular Dystrophy.

Authors:  Sarah M Schneider; Garett T Sansom; Lee-Jae Guo; Shinji Furuya; Brad R Weeks; Joe N Kornegay
Journal:  Front Vet Sci       Date:  2022-02-17

10.  The BDNF rs6265 Polymorphism is a Modifier of Cardiomyocyte Contractility and Dilated Cardiomyopathy.

Authors:  Frank J Raucci; Anand Prakash Singh; Jonathan Soslow; Larry W Markham; Lin Zhong; Wejdan Aljafar; Natasja Lessiohadi; Cassandra P Awgulewitsch; Prachi Umbarkar; Qinkun Zhang; Presley L Cannon; Maciej Buchowski; Joseph T Roland; Erica J Carrier; William B Burnette; Antonis K Hatzopoulos; Hind Lal; Cristi L Galindo
Journal:  Int J Mol Sci       Date:  2020-10-10       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.